Skip to main content Skip to main navigation menu Skip to site footer
logo Dermatology Reports

eISSN 2036-7406

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Archives
  • Early Access
  • Guidelines for Authors
  • Register
  • Login
  • Search
  • Contacts

Editor-in-Chief: Carlo Cota, Italy

1.0
Impact Factor 2025
1.5
CiteScore 2025
1.0
Impact Factor 2025
1.5
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

    Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
    12-11-2024
    https://doi.org/10.4081/dr.2024.10080
    1433
    PDF: 777
    HTML: 52
  • Treatment satisfaction among patients with psoriasis in Saudi Arabia

    Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi
    15-04-2024
    https://doi.org/10.4081/dr.2024.9967
    1155
    PDF: 669
    HTML: 55
  • The top 100 most cited articles in acne vulgaris: a bibliometric analysis

    Sapir Itzhaki Gabay, Barak Zlakishvili, Yuliya Valdman-Grinshpoun , Amir Horev
    15-02-2024
    https://doi.org/10.4081/dr.2024.9886
    3384
    PDF: 627
    SUPPLEMENTARY MATERIAL: 208
    HTML: 26
  • 26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL E. Filippi1, J. F. Merola2, P. Mease3, A. Kivitz4, N. Sattar5, L. C. Coates6, C. E. Kartman7, P. Fischer7, L. Sun7, A. Cardoso7, M. C. Genovese7, A. Ogdie8 | 1Eli Lilly Italia S.p.A, Florence, Italy; 2Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 3Providence Swedish Medical Center, Seattle, WA, USA; 4Altoona Center for Clinical Research, Duncansville, PA, USA; 5School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 7Eli Lilly and Company, Indianapolis, IN, USA; 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica
    24-09-2026
    https://doi.org/10.4081/dr.2026.11088
    147
    PDF: 60
  • Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

    Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota
    11-11-2024
    https://doi.org/10.4081/dr.2024.10140
    1120
    PDF: 588
    SUPPLEMENTARY MATERIAL: 190
    HTML: 24
  • HLA-Cw6 increases the risk of psoriasis and early onset before twenty-seven years of age among the Vietnamese population

    Nhi Thi Uyen Pham, Thuong Van Nguyen, Hao Trong Nguyen
    16-10-2023
    https://doi.org/10.4081/dr.2023.9854
    1486
    PDF: 569
    HTML: 57
  • Infliximab-induced intertriginous psoriasis in patient with Crohn's desease

    Federica Mola, Alberico Motolese
    e40
    03-10-2011
    https://doi.org/10.4081/dr.2011.e40
    1331
    PDF: 630
    HTML: 1095
  • Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

    Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
    19-05-2023
    https://doi.org/10.4081/dr.2023.9692
    1184
    PDF: 585
    HTML: 29
  • Acne exacerbation after tofacitinib treatment for alopecia areata

    Sawsan Alharthi, Mohammed G. Turkmani, Mohammed I. AlJasser
    01-01-2022
    https://doi.org/10.4081/dr.2022.9396
    2695
    PDF: 900
    HTML: 45
  • Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata

    Trang Thi Thuy Le, Thang Tat Nguyen, Chuyen Thi Hong Nguyen, Hao Trong Nguyen, Trung The Van
    27-10-2021
    https://doi.org/10.4081/dr.2021.9398
    3199
    PDF: 630
    HTML: 17
  • Two episodes of cutaneous non-tuberculous mycobacterial infection in a patient with psoriasis

    Wai Sze Agnes Chan, Shang-Ian Tee, Nisha Su Yien Chandran, Jiun Yit Pan
    15-06-2015
    https://doi.org/10.4081/dr.2015.5712
    2064
    PDF: 887
    HTML: 795
  • Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

    Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone
    29-07-2021
    https://doi.org/10.4081/dr.2021.8797
    3191
    PDF: 677
    HTML: 22
  • Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

    Paolo Dapavo, Matteo Megna, Marina Talamonti
    09-08-2024
    https://doi.org/10.4081/dr.2024.9999
    1892
    PDF: 780
    HTML: 110
  • Survey on the management and patient satisfaction levels in individuals with psoriasis and/or psoriatic arthritis

    Nicoletta Bernardini, Giuseppe Paolo Antonio Gemma, Nevena Skroza, Giuseppe Rizzuto, Ersilia Tolino, Pietro Scribani Rossi, Antonio Ricupito, Ilaria Proietti, Annunziata Dattola, Concetta Potenza
    19-02-2026
    https://doi.org/10.4081/dr.2026.10788
    396
    PDF: 244
  • Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

    Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris
    03-02-2026
    https://doi.org/10.4081/dr.2026.10644
    822
    PDF: 550
  • Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

    Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti
    01-07-2025
    https://doi.org/10.4081/dr.2025.10315
    669
    PDF: 344
    HTML: 28
  • Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

    Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
    30-07-2025
    https://doi.org/10.4081/dr.2025.10379
    623
    PDF: 452
    HTML: 15
  • Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

    Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly
    21-11-2022
    https://doi.org/10.4081/dr.2022.9265
    1592
    PDF: 477
    HTML: 41
  • Health-related quality of life and clinical characteristics of hidradenitis suppurativa in a pediatric population

    Anna Dattolo, Francesca Sampogna, Simona Mastroeni, Luca Fania, Davide Ciccone, Damiano Abeni
    16-10-2024
    https://doi.org/10.4081/dr.2024.10086
    919
    PDF: 566
    HTML: 42
26 - 44 of 44 items << < 1 2 

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a Scientific paper
  • How to write a Review article
  • Article Processing Charge
  • Crediti ECM (Italian Authors)

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to Review
  • Thanks to Reviewers

Categories

    • Newsletter
    • Original Articles
    • Reviews
    • Case Reports

indexing

INDEXING
  • PubMed
  • PubMed Central
  • Scopus
  • DOAJ
  • ESCI
  • Google Scholar
  • OpenAlex
  • Web of Science
  • Analytics

dermatopathology

Dermatopathology

Dermatology Reports

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

 

https://godisnjak.pf.unibl.org/

https://revistascientificas.us.es/

pISSN: 2036-7392
eISSN: 2036-7406

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.